# US 2020/0268735 A1 · Combination Therapy of Lasmiditan and a CGRP Antagonist for Use in the Treatment of Migraine

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2020/0268735 A1
- Document ID: US20200268735A1
- Status: Published application
- Kind: A1
- Application number: 16/643,668
- Filed: 2018-08-30
- Published: 2020-08-27
- Earliest claimed: 2017-09-06
- Assignees: Eli Lilly and Company
- Applicants: Eli Lilly and Company
- Inventors: Sheena Aurora; Kirk Willis Johnson; John Henry Krege
- Web page: https://patentgrep.com/patent/US20200268735A1

## CPC

- A61K 31/4545: containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
- A61K 31/517: ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
- A61K 39/3955: {against proteinaceous materials, e.g. enzymes, hormones, lymphokines}
- A61P 25/06: Antimigraine agents
- C07K 16/18: against material from animals or humans
- C07K 2317/24: containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

The present invention relates to combinations of lasmiditan and a calcitonin gene-related peptide (CGRP) antagonist, for example the combination of lasmiditan and galcanezumab, and to methods of using the combinations for treatment of migraine, particularly migraine inadequately controlled by lasmiditan or a CGRP antagonist therapy alone, and more particularly, to treat therapy resistant migraine which is defined herein as migraine refractory to two or more prior monotherapy and/or dual therapy treatment regimens.

## Claims

### Claim at position 1

1-30. (canceled)

### Claim 31

A method of treating migraine in a patient, comprising administering simultaneously, separately, or sequentially to a patient in need of such a treatment, an effective amount of lasmiditan in combination with an effective amount of a calcitonin gene-related peptide (CGRP) antagonist.

### Claim 32

A method of treating migraine in a patient, comprising administering simultaneously, separately, or sequentially to a patient in need of such a treatment, an effective amount of lasmiditan in combination with an effective amount of galcanezumab.

### Claim 33

A method of treating migraine in a patient, comprising administering simultaneously, separately, or sequentially to a patient in need of such a treatment, an effective amount of lasmiditan in combination with an effective amount of a calcitonin gene-related peptide (CGRP) antagonist, wherein migraine in the patient was inadequately controlled by lasmiditan or a CGRP antagonist therapy alone.

### Claim 34

A method of treating migraine in a patient, comprising administering simultaneously, separately, or sequentially to a patient in need of such a treatment, an effective amount of lasmiditan in combination with an effective amount of galcanezumab, wherein migraine in the patient was inadequately controlled by lasmiditan or galcanezumab therapy alone.

### Claim 35

A method of treating migraine in a patient, comprising administering simultaneously, separately, or sequentially to a patient in need of such a treatment, an effective amount of lasmiditan in combination with an effective amount of a calcitonin gene-related peptide (CGRP) antagonist, wherein the patient suffers from therapy resistant migraine wherein the patients migraines have been refractory to two or more prior monotherapy and/or dual therapy treatment regimens.

### Claim 36

A method of treating migraine in a patient, comprising administering simultaneously, separately, or sequentially to a patient in need of such a treatment, an effective amount of lasmiditan in combination with an effective amount of galcanezumab, wherein the patient suffers from therapy resistant migraine wherein the patients migraines have been refractory to two or more prior monotherapy and/or dual therapy treatment regimens.

### Claim 37 (depends on 32, 34)

The method of any one of claim 32, 34, or 36, wherein galcanezumab is administered in an initial loading dose of 240 mg of followed by a monthly maintenance dose of 120 mg, and lasmiditan is administered at a dose of 50 mg once or twice a day.

### Claim 38 (depends on 32, 34)

The method of any one of claim 32, 34, or 36, wherein galcanezumab is administered in an initial loading dose of 240 mg of followed by a monthly maintenance dose of 120 mg, and lasmiditan is administered at a dose of 100 mg once or twice a day.

### Claim 39 (depends on 32, 34)

The method of any one of claim 32, 34, or 36, wherein galcanezumab is administered in an initial loading dose of 240 mg of followed by a monthly maintenance dose of 120 mg, and lasmiditan is administered at a dose of 200 mg once a day.

### Claim 40 (depends on 32, 34)

The method of any one of claim 32, 34, or 36, wherein galcanezumab is administered at a monthly dose of 120 mg, and lasmiditan is administered at a dose of 50 mg once or twice a day.

### Claim 41 (depends on 32, 34)

The method of any one of claim 32, 34, or 36, wherein galcanezumab is administered at a monthly dose of 120 mg, and lasmiditan is administered at a dose of 100 mg once or twice a day.

### Claim 42 (depends on 32, 34)

The method of any one of claim 32, 34, or 36, wherein galcanezumab is administered at a monthly dose of 120 mg, and lasmiditan is administered at a dose of 200 mg once a day.

### Claim 43 (depends on 32, 34)

The method of any one of claim 32, 34, or 36, wherein galcanezumab is administered at a monthly dose of 120 mg, and lasmiditan is administered at a dose of 50 mg once a day.

### Claim 44 (depends on 32, 34)

The method of any one of claim 32, 34, or 36, wherein galcanezumab is administered at a monthly dose of 120 mg, and lasmiditan is administered at a dose of 100 mg once a day.

### Claim 45

(canceled)

### Claim 46

A method of treating a headache selected from the group consisting of episodic headache, chronic headache, chronic cluster headache, or episodic cluster headache in a patient, comprising administering simultaneously, separately, or sequentially to a patient in need of such a treatment, an effective amount of lasmiditan in combination with an effective amount of galcanezumab.

### Claim 47 (depends on 46)

The of claim 46, wherein headache in the patient was inadequately controlled by lasmiditan or a CGRP antagonist therapy alone.

### Claim 48 (depends on 46)

The of claim 46, wherein headache in the patient was inadequately controlled by lasmiditan or galcanezumab therapy alone.

### Claim 49 (depends on 46)

The of claim 46, wherein the patient suffers from therapy resistant headache wherein the patients headaches have been refractory to two or more prior monotherapy and/or dual therapy treatment regimens.

### Claim 50 (depends on 46, 47, 48)

The method of any one of claim 46, 47, 48, or 49, wherein galcanezumab is administered in an initial loading dose of 240 mg of followed by a monthly maintenance dose of 120 mg, and lasmiditan is administered at a dose of 50 mg once or twice a day.

### Claim 51 (depends on 46, 47, 48)

The method of any one of claim 46, 47, 48, or 49, wherein galcanezumab is administered in an initial loading dose of 240 mg of followed by a monthly maintenance dose of 120 mg, and lasmiditan is administered at a dose of 100 mg once or twice a day.

### Claim 52 (depends on 46, 47, 48)

The method of any one of claim 46, 47, 48, or 49, wherein galcanezumab is administered in an initial loading dose of 240 mg of followed by a monthly maintenance dose of 120 mg, and lasmiditan is administered at a dose of 200 mg once a day.

### Claim 53 (depends on 46, 47, 48)

The method of any one of claim 46, 47, 48, or 49, wherein galcanezumab is administered at a monthly dose of 120 mg, and lasmiditan is administered at a dose of 50 mg once or twice a day.

### Claim 54 (depends on 46, 47, 48)

The method of any one of claim 46, 47, 48, or 49, wherein galcanezumab is administered at a monthly dose of 120 mg, and lasmiditan is administered at a dose of 100 mg once or twice a day.

### Claim 55 (depends on 46, 47, 48)

The method of any one of claim 46, 47, 48, or 49, wherein galcanezumab is administered at a monthly dose of 120 mg, and lasmiditan is administered at a dose of 50 mg once a day.

### Claim 56 (depends on 46, 47, 48)

The method of any one of claim 46, 47, 48, or 49, wherein galcanezumab is administered at a monthly dose of 120 mg, and lasmiditan is administered at a dose of 100 mg once a day.

### Claim 57 (depends on 46, 47, 48)

The method of any one of claim 46, 47, 48, or 49, wherein galcanezumab is administered at a monthly dose of 120 mg, and lasmiditan is administered at a dose of 200 mg once a day.
